In the News | Press Highlights
Citizen is building an AI advocate that can summarize personal health data, ideally making it easier to use those data in future doctor’s appointments. As a standalone company, Vij said, it can move faster than it might have inside a larger company, especially as AI speeds up what teams are able to do.
Read more
A Consumer Platform to Drive Better Rare Disease Prognoses for One and All; Our Investment in Citizen Health’s Series A
August 14, 2025
Mathias Schilling, Matt Brown, & Georgina McMillan
See moreAt its core, Citizen Health is building a beautiful consumer platform that brings together every piece of a patient’s health journey—clinical data, genetic information, imaging, patient-reported outcomes, and claims.
Read more
Citizen Health Raises $30 Million to Build AI Advocate for Every Patient, Ushering in a New Era of Patient-Centered Healthcare
August 14, 2025
See moreCitizen Health, a patient-powered platform transforming rare disease care, announced today it has raised $30 million in Series A funding. The round was led by 8VC, with participation from Transformation Capital and Headline, bringing the company's total funding to $44 million since its December 2023 launch.
Read more
Why it matters: Citizen aims to equip people with rare diseases, who often face medical dead ends, with an AI-powered advocate to navigate care and interpret records.
Read more
“We have our own proprietary database that we have built from scratch over many years to pull together every single e-fax number, every single email for every health information management department or medical records department,” for every single provider or hospital institution in the U.S., Citizen CEO Farid Vij told ...
Read more
Two groups of parents dreamed the impossible — clinical trials for their kids' rare diseases. Now they're close to making it happen
August 4, 2025
Ron Leuty
See moreThere was little hope only a few years ago of treatments for kids with ultrarare SLC13A5 or FOXG1 syndromes. Drug companies were loathe to take on the cost of discovering and developing therapies, much less expensive and risky clinical trials, for genetic conditions with only a couple hundred patients.
Read more
Gemini momentum continues with launch of 2.5 Flash-Lite and general availability of 2.5 Flash and Pro on Vertex AI
June 17, 2025
Jason Gelman
See more"We orchestrate Gemini 2.5 Flash and Gemini 2.5 Pro models within a LangGraph‑powered multi‑agent framework, ensuring the most relevant evidence reaches patients and caretakers without hallucinations." - Daniel Wang, CTO, Citizen Health
Read more
Healthcare data sharing is evolving rapidly across CMS, ONC, and the entire industry. In this first episode of InteropChat, we brought together four top experts to break down what's happening and what's next.
Read more
"It has been several years since I last wrote a blog post about SCN8A. A wide range of clinical presentations have been described since, and significant progress has been made towards understanding the disease mechanism. However, SCN8A-related disorders have not become less puzzling."
Read more
Critical Path Institute® (C-Path) and Citizen Health Partner to Accelerate Drug Development for Neuromuscular Disorders
May 29, 2025
See moreTogether, the organizations will establish a partnership focused on neuromuscular disorders, including limb-girdle muscular dystrophies (LGMDs), Charcot-Marie-Tooth (CMT) disease, nemaline myopathy (NM), myotonic dystrophies, and related conditions.
Read more
PODCAST: Rethinking Rare: The Future of Rare Disease Research (S3:E5)
May 20, 2025
ACRO's Good Clinical Podcast (GCP)
See moreOn this episode, Tania Simoncelli (Vice President, Translational Impact and Engagement, Chan Zuckerberg Initiative) and Nasha Fitter (Co-founder & CBO, Citizen Health and Co-founder & CEO, FOXG1 Research Foundation) join forces to discuss how rare disease patient advocacy has transformed over time and how the biopharmaceutical industry should adapt to better meet the needs of today’s patients.
Read moreCitizen Health Partner to Support Drug Development and Long-Term Patient Outcomes in PKP2 Cardiomyopathy
May 7, 2025
See moreCitizen Health today announced a strategic partnership to support Rocket Pharmaceutical Inc.'s (Rocket Pharma) clinical and long-term data initiatives for arrhythmogenic cardiomyopathy (ACM) caused by mutations in the PKP2 gene.
Read more
